Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270Phase 2Recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Dec 2021
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of 4D-150 in neovascular age-related macular degeneration (NVAMD) (10 arms), sponsored by 4D Molecular Therapeutics. Primary endpoint: Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) at 52 weeks. Started Dec 2021; status: recruiting.
02
Drugs
4D-150
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05197270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197270.